Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Dexlansoprazole

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    10 result(s) found for: Dexlansoprazole. Displaying page 1 of 1.
    EudraCT Number: 2014-004507-73 Sponsor Protocol Number: TAK-390MR_205 Start Date*: 2016-02-26
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 2, Double Blind, Up to 40 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Es...
    Medical condition: Erosive Esophagitis in paediatric subjects aged 1 to 11 years
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Prematurely Ended) PT (Completed) BE (Completed) PL (Trial now transitioned) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-004506-15 Sponsor Protocol Number: TAK-390MR_204 Start Date*: 2015-12-10
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 2, Double-Blind, 12 Week, Multicenter Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules in Pediatric Subjects Aged 1 to ...
    Medical condition: Symptomatic nonerosive GERD in paediatric subjects aged 1 to 11 years
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) IT (Prematurely Ended) PT (Completed) PL (Trial now transitioned) LT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2014-001642-16 Sponsor Protocol Number: TAK-390MR_108 Start Date*: 2015-04-24
    Sponsor Name:Takeda Development Centre Europe Ltd.
    Full Title: A Phase 1, Randomized, Open-Label, Parallel-Design, Multicenter Study to Evaluate the Pharmacokinetics, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Capsules in Infants Aged 1 ...
    Medical condition: Acid-Related Disorders in Infants aged 1 to 11 months
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    17.1 100000004856 10000479 Acid reflux (oesophageal) LLT
    17.1 100000004856 10019326 Heartburn LLT
    17.1 100000004856 10063657 Erosive esophagitis LLT
    Population Age: Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Temporarily Halted) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-001681-15 Sponsor Protocol Number: TAK-390MR_207 Start Date*: 2012-10-17
    Sponsor Name:Takeda Global Research & Development Centre (Europe) Ltd
    Full Title: A Phase 2 Multicenter, 36-Week Study to Assess the Safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Healing of Erosive Esophagitis and Maintenan...
    Medical condition: Heartburn and Erosive Esophagitis in Adolescent Subjects
    Disease: Version SOC Term Classification Code Term Level
    14.1 10017947 - Gastrointestinal disorders 10018203 GERD LLT
    14.1 10017947 - Gastrointestinal disorders 10019326 Heartburn LLT
    14.1 10017947 - Gastrointestinal disorders 10063657 Erosive esophagitis LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) BE (Completed) PT (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-001680-72 Sponsor Protocol Number: TAK-390MR_206 Start Date*: 2012-10-09
    Sponsor Name:Takeda Development Centre Europe Ltd
    Full Title: A Phase 2 Open-Label, Multicenter, 4-Week Study to Assess the safety and Effectiveness of Daily Oral Administration of Dexlansoprazole Delayed-Release Capsules for Relief of Heartburn, in Adolescen...
    Medical condition: Heartburn in Adolescent subjects With Symptomatic Non-Erosive Gastroesophageal Reflux Disease
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004856 10066874 Gastroesophageal reflux disease LLT
    14.1 100000004856 10019326 Heartburn LLT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) PT (Completed) BE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2005-001189-15 Sponsor Protocol Number: T-EE04-086 Start Date*: 2006-03-07
    Sponsor Name:TAP Pharmaceutical Products Inc.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis
    Medical condition: Erosive esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) CZ (Completed) GB (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-001190-10 Sponsor Protocol Number: T-EE04-087 Start Date*: 2006-03-07
    Sponsor Name:TAP Pharmaceutical Products Inc.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis
    Medical condition: Erosive esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LT (Completed) CZ (Completed) GB (Prematurely Ended) LV (Completed)
    Trial results: View results
    EudraCT Number: 2006-000419-90 Sponsor Protocol Number: T-EE05-135 Start Date*: 2006-06-16
    Sponsor Name:TAP Pharmaceutical Products Inc.
    Full Title: A Phase 3 Study to Evaluate the Safety and Efficacy of TAK-390MR (30 mg QD and 60 mg QD) Compared to Placebo in Maintenance of Healing in Subjects with Healed Erosive Esophagitis
    Medical condition: Erosive esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) HU (Completed) SK (Completed) CZ (Completed) LT (Completed) LV (Completed)
    Trial results: View results
    EudraCT Number: 2005-001187-31 Sponsor Protocol Number: T-EE04-084 Start Date*: 2006-03-06
    Sponsor Name:TAP Pharmaceutical Products Inc.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive Esophagitis
    Medical condition: Erosive esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) CZ (Completed) DE (Completed) GB (Prematurely Ended) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2005-001188-70 Sponsor Protocol Number: T-EE04-085 Start Date*: 2006-03-06
    Sponsor Name:TAP Pharmaceutical Products Inc.
    Full Title: A Phase 3 Study to Evaluate the Efficacy and Safety of TAK-390MR (60 mg QD and 90 mg QD) and an Active Comparator, Lansoprazole (30 mgQD) on Healing of Erosive Esophagitis
    Medical condition: Erosive esophagitis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: EE (Completed) LV (Completed) LT (Completed) CZ (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 14 11:44:27 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA